Qube Research & Technologies LTD Clearside Biomedical, Inc. Transaction History

Qube Research & Technologies LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.08 - $1.58 $5,832 - $8,532	-5,400 Reduced 99.93%	4 $0
Q1 2024 May 14, 2024	BUY	$1.2 - $2.02 $6,480 - $10,908	5,400 Added 135000.0%	5,404 $8,000
Q3 2023 Nov 13, 2023	BUY	$0.82 - $1.27 $3 - $5	4 New	4 $0
Q4 2021 Feb 01, 2022	SELL	$2.72 - $5.72 $70,216 - $147,661	-25,815 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.83 - $7.2 $124,686 - $185,868	25,815 New	25,815 $155,000
Q2 2021 Aug 13, 2021	SELL	$2.32 - $5.38 $42,237 - $97,948	-18,206 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$2.24 - $4.25 $164,881 - $312,834	-73,608 Reduced 80.17%	18,206 $45,000
Q4 2020 Feb 16, 2021	SELL	$1.32 - $2.74 $23,098 - $47,947	-17,499 Reduced 16.01%	91,814 $252,000
Q3 2020 Nov 12, 2020	BUY	$1.45 - $2.0 $101,573 - $140,102	70,051 Added 178.42%	109,313 $168,000
Q2 2020 Aug 14, 2020	BUY	$1.55 - $2.41 $60,856 - $94,621	39,262 New	39,262 $74,000

12.2M

54.7K

50.7K

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $52.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.